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Pituitary adenomas (PAs) are adenohypophysial neoplasms, representing ~10–15% of all
intracranial tumors, which are found to occur in almost 20% of the general population (1, 2).
Although recognized as benign lesions, 20–45% of PAs are invasive and some exhibit clinically
aggressive behavior (1, 3). Advancements have allowed the pathological classification of PAs
from a histochemical classification (i.e., acidophilic, basophilic, and chromophobic PAs) to an
immunohistochemical-based one, which essentially recognizes PAs as lactotrophic, somatotrophic,
corticotrophic, gonadotrophic, thyrotrophic, and null cell adenomas (4). Electron microscopy has
identified additional subtypes, based on the appearance of specific morphology/arrangement of
ubiquitous cytoplasmic constituents (5). It is now accepted that the hypothalamic–anterior pituitary
axis integrates a set of stimulatory and inhibitory central and peripheral signals to synthesize
and secrete hormones by highly differentiated cell types, namely somatotrophs, gonadotrophs,
lactotrophs, thyrotrophs, and corticotrophs. Each of these cell types expresses unique G protein-
coupled receptors (GPCRs), which are specific for hypothalamic releasing and inhibiting hormones.
These peptides traverse the vascular system that connects the hypothalamus with the anterior
pituitary gland and impinge upon the pituitary cells to regulate the synthesis and secretion of anterior
pituitary hormones (6). It has been demonstrated that PAs arise from any of these cells asmonoclonal
neoplasms (7). The functional classification of PAs has also been facilitated by the measurement of
circulating trophic and target hormone concentrations (6). Several hallmarks of PAs (i.e., benign
nature, slow growth) point to a unique growth behavior distinct from that of other endocrine
and non-endocrine malignancies (8). The general failure to proceed to true malignancy with
demonstrable extra-cranial metastases remains an intriguing feature not completely investigated yet
(8). Atypical and/or aggressive PAs can share some histological features with carcinomas, including
atypical morphologic appearances, elevated mitotic index (i.e., Ki-67 labeling index>3%), or exten-
sive nuclear staining for p53 (9). Nonetheless, the endocrine signs due to hormonal hypersecretion or
pituitary deficit, pituitary abnormal growth, or invasion represent a greater clinical and therapeutic
challenge (8). The subset of PAs with clinically aggressive behavior should be promptly identified,
as patients with such tumors might require closer clinical, biochemical, and imaging surveillance
or multimodal therapeutic treatments. Despite the paramount importance of identifying specific
criteria for tumor aggressiveness, no clinical signs, biochemical biomarkers, or imaging techniques
have been universally accepted and no reliable histological biomarker or classification system for
characterizing pituitary aggressive neoplasms are available today (10). It has also been suggested that
the histological features of “typical” and “atypical” PAs as defined by theWorld Health Organization
(WHO) do not entirely correlate with clinical outcome. In particular, some typical PAs have an
aggressive behavior whilemany atypical PAs lack an aggressive clinical dynamics (1, 7). Additionally,
the lack of standardization of the terminology in the literature remains a source of confusion (i.e.,
the terms “aggressive” and “invasive” are often used synonymously).
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Although the molecular pathogenesis of PAs is still unclear,
it is now accepted that PAs onset is related to proto-oncogene
mutations, overexpression of activating genes, or loss of tumor
suppressor genes (11). The “initiating” events cause a proliferative
“gain of function” in single pituitary cells, subsequently induced
to clonal expansion by tumor-promoting molecules. Recently,
several studies have shown the pivotal role of “epigenetic mod-
ifications” (11, 12), microRNA (miRNAs), and long non-coding
RNAs (lncRNAs) in the pathogenesis of PAs (13–17). Other pro-
moting factors, including hypothalamic hormones, locally pro-
duced growth factors (i.e., EGF, βFGF, NGF, and TGF), cytokines
[interleukin (IL)-1, IL-2, and IL-6], and chemokines have been
shown to influence pituitary tumor progression (18, 19).
Chemokines represent a category of inflammatory mediators
with a prominent role in leukocyte migration and angiogenesis,
exerted through the activation of dedicated seven-transmembrane
domain receptors, known as GPCRs (20, 21). Beyond conven-
tional chemokine receptors, which directly induce cell migration
throughGi-mediated signaling events, a set of atypical chemokine
receptors (ACKRs) with no Gi-mediated signaling activity and
devoid of chemotactic activity have been described (22). Recent
data indicate that ACKRs fulfill their biological functions by
contributing to generate and maintain functional chemokine pat-
terns in tissues by means of different biochemical properties,
including removal, transport, or concentration of their cognate
ligands (23). Deregulated expression of chemokines and their
receptors is involved in the development of many human dis-
eases, including autoimmune and chronic inflammatory diseases,
immunodeficiency, and cancer (24). In the adult central ner-
vous system (CNS), chemokines and their receptors are involved
in developmental, physiological processes and nervous system
disorders, including neuroinflammatory and neurodegenerative
diseases, HIV-associated neuropathology, and brain tumors (25–
27). In particular, theC–X–C chemokine receptor type 4 (CXCR4)
and its ligand stromal cell-derived factor 1 [SDF1, also known
as C–X–C motif chemokine 12 (CXCL12)] are expressed by
neuronal, astroglial, and microglial cells in the adult brain and
play a critical role in supporting cell growth and survival, and
directing cell migration during embryonic brain development
(28–31). Moreover, the CXCL12/CXCR4 axis has been found in
malignant tumors, includingmeningiomas, gliomas, where it cru-
cially affects tumor progression by controlling cancer cell survival,
proliferation, and migration, and, indirectly, regulating angio-
genesis and vasculogenesis or recruiting fibroblasts, endothelial,
mesenchymal, and immune cells in tumormicroenvironment (32,
33). Regulation of CXCL12 is unique in that it may control its
own expression levels and fine tune its biological functions by
means of its binding to the ACKR CXCR7/ACKR3 in addition
to CXCR4, which has been reported to regulate angiogenesis in
different human tumors through its own signaling activity (34).
ACKR3 has been found simultaneously expressed with CXCL12
and CXCR4 in a cohort of brain metastases (35). Therefore, the
CXCL12/CXCR4/ACKR3 pathway could be investigated to tar-
get tumor growth, invasion, and proliferation of metastatic cells.
Additionally, it opens new perspectives in the development of spe-
cific therapeutic approaches that include chemokine-based drugs.
Interestingly, the CXCR4 antagonist Plerixafor (also known as
AMD3100) is already Food and Drugs Administration-approved
for stem cell mobilization in several tumors, including non-
Hodgkin’s lymphoma and multiple myeloma (36, 37) and its
systemic administration has been reported to inhibit growth
of intracranial glioblastoma and medulloblastoma xenografts by
increasing apoptosis and decreasing the proliferation of tumor
cells (38).
Recently, several chemokines (i.e., CXCL1, CXCL10, CXCL12)
have been identified as novel regulators of the hypothala-
mic–hypophysial axis. However, only a few studies addressed their
role in the regulation of normal and tumor pituitary cell functions.
In particular,
(a) CXCL1 is indeed expressed in the posterior pituitary gland,
in the paraventricular nucleus of the hypothalamus and the
median eminence. In response to stressful stimuli, CXCL1 is
released in the median eminence to reach its receptor CXCR2
expressed in pituitary cells and induce the release of PRL
and GH along with the inhibition of LH and FSH secretion
(39). CXCL1 was detected in a small percentage of human
PAs and CXCR2 was identified in both human PAs without
a tumor-specific phenotype and natural pituitary tissue (40).
(b) The CXCL10 receptor CXCR3 has been reported to
be expressed in corticotrophs, suggesting a possible
autocrine/paracrine effect of CXCL10, released from FSH
cells, on ACTH-producing cells (41).
(c) Differently from rats (42), CXCR4 expression was confined
to a subset of pituitary cells but not to a specific cell sub-
population (i.e., GH-, PRL- or ACTH-secreting cells). The
CXCR4 ligand CXCL12 has been identified mostly but not
exclusively in ACTH-expressing pituitary cells (43, 44). It
may be hypothesized that CXCR4/CXCL12 axis could be
expressed in undifferentiated and/or progenitor cells and
contribute to the paracrine regulation of pituitary hormone
secretion. In this perspective, the possibility that pituitary
CXCR4 should also be activated by the chemokine derived
from the systemic circulation or fromhypothalamic terminals
cannot be excluded. Recently, several studies have revealed
the expression of CXCL12 and/or CXCR4 in human pitu-
itary tumors, suggesting that this chemokine may act as a
promoting factor for adenoma development (43). Barbieri
et al. have investigated the expression of both CXCL12 and
CXCR4 in a cohort of 65 human PAs and 4 normal hypophy-
ses and the potential autocrine–paracrine role of CXCL12
in pituitary cell proliferation (44). They provided the first
evidence of CXCL12 and CXCR4 expression in normal and
adenomatous human pituitary, and showed that overexpres-
sion of both ligand and receptor occurs in all the adenomatous
cells compared with normal pituitary cells, thus suggesting
their role in providing a gain-of-function to pituitary cells
by affecting both cell proliferation and hormone secretion,
thus contributing to PA development and/or progression.
Differently from normal pituitary cells that do not co-express
CXCL12 and CXCR4, concomitant expression of both ligand
and receptor occurs in PAs, suggesting that autocrine stim-
ulation of CXCR4 seems to represent a key characteristic of
PAs. Xing et al. investigated the expression of CXCR4 and
CXCL12 in 35 PAs (21 invasive and 14 non-invasive) patients
whounderwent surgical resection, anddemonstrated that that
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there was a positive correlation between the level of CXCR4
andCXCL12 and the progression stage of PAs, suggesting that
CXCR4 and CXCL12 played a role in the regulation of PAs
invasiveness (45). Further studies will be required to verify
whether CXCL12 overexpressionmay cause PAs development
or only provide a selective proliferation advantage favoring
clonal expansion of cells in which tumor-promoting mech-
anisms are already activated. Moreover, the general lack of
progression from PA to carcinoma and metastatic status sug-
gests further studies to investigate the potential involvement
of CXCL12/CXCR4 axis. Interestingly, ACKR3 was expressed
by all the PAs, especially in GH and PRL secreting adenomas
and itwas observed that its expressionwas significantly higher
in macro- than micro-adenomas (46).
It is known that that the concomitant expression of lig-
and–receptor in the same tumor cells is one of the leading
causes of clinical aggressive behavior in various cancer types. It
is known that Raf/MEK/ERK and PI3K/Akt pathway deregula-
tion is a common alteration responsible of tumor initiation and
progression in melanoma (47). While the pathways are classically
activated by growth factors, crosstalk and transactivation mech-
anisms with neuropeptide–cytokine–chemokines/GPCRs have
been increasingly recognized. It has been shown that the over-
expression or constitutive activation of receptors for growth fac-
tors, cytokines, and chemokines potentiates the activation of
Ras/Raf/MEK/ERK pathway also in PA (48–50). Chemokines,
particularly CXCL12 signaling via CXCR4 and ACKR3, rep-
resent candidate mediators of the above-described intracel-
lular pathways, determining proliferative, antiapoptotic, and
angiogenic signals, thus possibly concurring to pituitary tumor
development and aggressiveness. Therefore, the better charac-
terization of CXCR4/ACKR3/CXCL12 axis in PAs (Figure 1)
could pave the way for novel pharmacological approaches, espe-
cially for those adenoma subtypes (i.e., TSH and ACTH-secreting
tumors, as well as NFPA) still waiting for efficacious thera-
peutic drugs. Other studies, however, highlighted that, when
considering the complexity of regulatory pathways involved
in pituitary cell survival and proliferation, it should be taken
into account not only apoptosis but also the cellular “senes-
cence.” Senescence is gaining biological significance also in
PAs, whose typical benign nature could result from protec-
tive anti-proliferative mechanisms. PAs may be prone to acti-
vate senescence-associated pathways, maintaining their benign
behavior and preventing malignant transformation. Furthermore,
autophagy-related mechanisms in pituitary tumors are still under
investigation (51, 52).
Cancer research has undergone radical changes over the last
few years. The issue today is no longer the amount of molecular,
cellular, and clinical information available, but the network inter-
actions among the single components (53, 54). Systems biology is
the latest in a series of strategies driven by technological advances
that have provided us with a suite of “omics” (55). The “analytic”
and the “systemic” approaches are more complementary than
FIGURE 1 | Functional roles of the CXCR4/ACKR3/CXCL12 axis in pituitary adenomas.
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opposed, yet neither one is reducible to the other. The analytic
approach seeks to reduce a system to its elementary elements in
order to study in detail and understand the types of interaction
that exist between them. The “additive” laws of elementary prop-
erties do not apply in complex systems, i.e., PAs, composed of a
large diversity of elements linked together by complex interac-
tions. These systemsmust be approached by newmethods such as
those, which the systemic approach groups together. The purpose
of the new methods is to consider a system as a “whole,” its com-
plexity, and its own dynamics. In conclusion, although the role
of chemokines in PA development has been poorly investigated,
the evaluation of CXCR4 and CXCL12 expression in invasive
and non-invasive PAs has demonstrated that the percentage of
CXCR4- and CXCL12 positive cells was significantly higher in
invasive PAs. Therefore, the correlation of CXCR4 and CXCL12
expression levels and tumor invasiveness might be proposed as
potential early diagnostic biomarkers (56). Scientific advances
are revealing the complexity of pituitary development and its
microenvironment, which is controlled by multiple transcription
factors and signaling molecules. These results strengthen the
idea that to target chemokine networks might represent a novel
therapeutic approach for PAs.
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